Navigation Links
CTI Announces Data Presentations at the 55th American Society of Hematology Annual Meeting
Date:11/7/2013

ubject to a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities.  Such statements include, but are not limited to, statements regarding CTI's expectations with respect to the development of CTI and its product and product candidate portfolio, the expected commencement of the PERSIST-2 clinical trial in the fourth quarter of 2013 and the expected efficacy and potential benefits of pacritinib (including that pacritinib may offer an advantage over other JAK inhibitors through effective treatment of symptoms while having less treatment-emergent thrombocytopenia and anemia than has been seen in currently approved and in-development JAK inhibitors).  Risks that contribute to the uncertain nature of the forward-looking statements include, among others, risks associated with the biopharmaceutical industry in general and with CTI and its product and product candidate portfolio in particular including, among others, risks associated with the following: that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials, that CTI cannot predict or guarantee the outcome of preclinical and clinical studies, that the second Phase 3 clinical trial of pacritinib will not occur as planned, that CTI may not obtain favorable determinations by other regulatory, patent and administrative governmental authorities, that CTI may experience delays in the commencement of preclinical and clinical studies, risks related to the costs of developing pacritinib and CTI's other product candidates, and other risks, including, without limitation, competitive factors, technological developments, that CTI's operating expenses continue to exceed its net revenues, that CTI may not be able to sustain its current cost controls or further reduce its operating expenses, that CTI may not achieve previously announced goals and objectives as or when projected, that C
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ambit Biosciences Announces Third Quarter 2013 Operating Results
2. Spherix Announces the Closing of Private Placement of $2,235,000
3. Intelligent Implant Systems Announces 510(k) Clearance of the Marauder Cervical-Thoracic Spinal System
4. karmadata Announces Launch Of App Gallery And The Indicate Investigators App
5. Spherix Announces Additions to Technology Advisory Board in Areas of Licensing and Litigation Support
6. InterMune Announces Pricing of Public Offering of 6,500,000 Shares of Common Stock
7. AVS announces its major award winners of 2013
8. Metabolix Announces Third Quarter 2013 Financial Results
9. Discovery Labs Announces Completion of $50 Million Public Offering
10. Life Technologies Announces Third Quarter 2013 Results
11. Colby Pharmaceutical Company Announces Dramatic Results: Novel Technology Increases Influenza Vaccine Protection for Elderly Rhesus Monkeys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 05, 2015 Research ... has announced the addition of the ... to their offering. Macromolecules which ... undergo separation or are broken into smaller ... products. This separation requires various advanced systems ...
(Date:5/5/2015)... DIEGO , May 5, 2015  Renova™ ... for congestive heart failure and other chronic diseases, ... an independent analysis designed to reflect the healthcare ... time. This model will be used to characterize ... CHF, could have on those groups of patients ...
(Date:5/5/2015)... D.C., USA (PRWEB) May 05, 2015 ... regulations covering a wide range of key photonics technologies ... hampering global competitiveness of U.S. industry. To help the ... webinar on 12 May on the proposed changes ... the commodities covered by International Traffic in Arms Regulations ...
(Date:5/5/2015)... FRANCISCO, Calif. , May 5, 2015 ... treatment of cancer, today announced that Sean McCarthy ... the Credit Suisse Antibody Day in New ... May 6. Dr. McCarthy will present an overview of ... and Probody drug conjugate programs. About CytomX ...
Breaking Biology Technology:Global Separation Systems Market in Biotechnology 2015-2019 - Trends and Forecasts for the $28 Billion Market 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3Comments needed now from photonics industry on revisions of U.S. export rules 2Comments needed now from photonics industry on revisions of U.S. export rules 3Comments needed now from photonics industry on revisions of U.S. export rules 4
... 8 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ADLS ... and live webcast at 9:00 a.m. Eastern Time on ... financial results.,Michael T. Flavin, Ph.D., Chairman & Chief Executive ... present an update on the Company.,A press release reporting ...
... Calif., Nov. 7 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation ... nine months of 2007 were $6,214,712,an increase of 567% ... Revenues for the third quarter of 2007 were ... third quarter of 2006. These significant,increases are due to ...
... at 1:30 p.m. (Pacific); ... http://www.adventrx.com , SAN DIEGO, Nov. 7 ... and development company,focused on commercializing proprietary product candidates for ... results for,the three-month and nine-month periods ended September 30, ...
Cached Biology Technology:Advanced Life Sciences to Host Third Quarter 2007 Financial Results Conference Call and Live Webcast 2Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 2Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 3Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 4Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 5Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 6Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 7Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 8Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 9ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 2ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 3ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 4ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 5ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 6ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 7
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... NYU Langone Medical Center,s Departments of Orthopaedic Surgery and ... to detect subtle changes in joint cartilage microstructure ... markers of early osteoarthritis (OA). By using these techniques ... shift the management of the disease from eventual joint ...
... The last century has seen two major pandemics caused ... and 2009,s Swine Flu scare, which had thousands travelling with ... know what distinguished the Swine Flu from ordinary influenza in ... to travel extensively and infect large populations. Until now. ...
... MO, August 15, 2011A compound found in green tea ... treat two types of tumors and a deadly congenital ... led by Principal Investigator, Dr. Thomas Smith at The ... The Children,s Hospital of Philadelphia. Their findings are published ...
Cached Biology News:NYU Langone experts find MRI techniques can detect early osteoarthritis 2Could the Spanish flu devastate us again? 2Researchers demonstrate green tea is effective in treating genetic disorder and types of tumors 2
Polyclonal Antibody to AGAP1 / Centaurin, gamma 2...
Mouse monoclonal [b/e4 (9.20)] to Cytochrome P450 2B1 + 2B2 ( Abpromise for all tested applications)....
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Biology Products: